Myra Medical, a Campbell, Calif.-based newly formed Shifamed portfolio company advancing surgical devices to enable maximum intraocular pressure (IOP) reduction, raised $3.16m in seed funding.
Backers included Shifamed accredited angel investors.
The company intends to use the funds to advance product development and pre-clinical programs.
Myra Medical is evolving the surgical device landscape with a novel technology that aims to provide physicians and patients with an effective platform to safely enable maximum intraocular pressure (IOP) reduction while reducing the risk of hypotony, improving treatment for moderate to advanced glaucoma patients
Shifamed also announced the appointments of Robert Chang to serve as Myra Medical’s Chief Executive Officer and Tracy Valorie, seasoned ophthalmology executive, to serve as strategic advisor to the company.
Robert Chang joins Myra Medical with over 30 years of executive and medical device development experience. Most recently, Mr. Chang was the Co-Founder, President, CEO and Director at MVRx, Inc. Prior to this, Chang served as Executive Vice President and Chief Technology Officer of Sadra Medical, a legacy company of Shifamed, acquired by Boston Scientific Corporation. Prior to his time with Sadra, Chang co-founded Ample Medical, serving as their President, CEO and Director.
Tracy Valorie advises Myra Medical with over 25 years of experience and most recently serving as the Senior Vice President, General Manager of the U.S. Pharmaceutical and Surgical businesses at Bausch + Lomb. Previously, Ms. Valorie was the Commercial Lead of Ophthalmology at Pfizer, with responsibility for multiple global Ophthalmology brands and commercial development of mid-stage portfolio and long-range strategic planning.
Founded by serial entrepreneur Amr Salahieh, Shifamed is a highly specialized medical innovation hub focused on developing solutions that accelerate time to market, reduce risk, increase impact, and forge a path toward a world where patients are able to lead longer, healthier lives.
FinSMEs
10/10/2019